Business Context and Reporting Period
This Form 8-K, dated March 16, 2023, reports on the extraordinary general meeting of JATT Acquisition Corp (JATT), a Cayman Islands exempted company. The filing details the shareholder vote to approve a business combination with Zura Bio Limited (Zura), a biopharmaceutical company. The meeting was held to ratify the Business Combination Agreement originally dated June 16, 2022, and subsequently amended.
Key Financial Metrics and Voting Results
The filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics for either JATT or Zura. The primary quantitative data provided relates to the shareholder vote:
- Record Date: February 16, 2023
- Shares Outstanding: 5,138,978 Ordinary Shares
- Shares Present/Voted: 4,907,863 (95.5% of voting power)
- Business Combination Proposal: 4,903,764 votes For; 4,099 votes Against; 0 Abstentions
- Corporate Name Change: Approved to change from "JATT Acquisition Corp" to "Zura Bio Limited"
- Authorized Capital: Approved increase to 300,000,000 Class A ordinary shares
Material Changes and Proposals Approved
Shareholders approved a comprehensive set of proposals necessary to consummate the merger:
- Business Combination: Adoption of the agreement to merge JATT with Zura.
- Corporate Structure: Change of name to Zura Bio Limited, perpetual existence, and elimination of blank check company provisions.
- Governance: Approval of advisory governance proposals, including board size determination and removal of directors (notably, Proposal B and D received significant "Against" votes of 548,090, though they still passed).
- Board Composition: Election of seven new directors: Someit Sidhu, Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett, and Neil Graham.
- Equity Plans: Approval of the Zura Bio Limited 2023 Equity Incentive Plan and Employee Share Purchase Plan (ESPP).
- Listing: Approval of the issuance of more than 20% of outstanding shares to comply with NYSE listing rules.
Outlook, Risks, and Contingencies
The filing includes extensive forward-looking statements regarding the anticipated financial impacts and timing of the Business Combination. Management highlighted several material risks that could prevent the transaction from closing or alter expected outcomes:
- Closing Conditions: Failure to satisfy conditions precedent, including regulatory approvals.
- Timing: Risk of not meeting the Business Combination deadline or failing to obtain an extension.
- Capital Needs: Potential inability to raise additional capital required for business objectives.
- Operational Risks: Disruption of operations, retention of key employees, and competition.
- Legal and IP: Potential legal proceedings, intellectual property enforceability, and cybersecurity risks.
- Market Factors: Volatility in securities prices and the impact of the global COVID-19 pandemic.
Investor Verification Checklist
- Verify the final closing date of the Business Combination and whether all regulatory conditions have been met.
- Review the definitive Proxy Statement (filed March 1, 2023) for detailed financial projections and capitalization tables not included in this 8-K.
- Confirm the ticker symbol change and delisting of JATT securities from the NYSE upon consummation.
- Assess the specific terms of the new Equity Incentive Plan and ESPP for potential dilution impacts.
- Monitor for any legal challenges or regulatory delays that could trigger the termination of the Business Combination Agreement.